Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862364 | 0.83 | KDM4E (0.58) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL2062310 | 0.82 | ALOX15 (0.46) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL27847545 | 0.82 | ALOX15 (0.46) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL11090176 | 0.79 | ALOX15 (0.53) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL7665459 | 0.79 | ALOX15 (0.46) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL24413725 | 0.79 | KDM4E (0.50) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL6652480 | 0.78 | ALOX15 (0.43) | SLC7A5ALOX15CA12CA1CA2 | |
| SCHEMBL4820728 | 0.78 | PRKCI (0.50) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL28763271 | 0.77 | KDM4E (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7265177 | 0.77 | USP2 (0.49) | SLC7A5ALOX15CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193609-A | 1, 4-naphthoquinone derivatives and therapeutic uses thereof | CENTRE NAT RECH SCIENT | 2014-12-10 | — | — | CN | disclosed |
| CN-102015607-A | 1, 4-naphthoquinone derivatives and therapeutic uses thereof | CENTRE NAT RECH SCIENT | 2011-04-13 | — | — | CN | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| CN-101790512-A | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel | ALBIREO AB | 2010-07-28 | — | — | CN | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| CN-100522961-C | Amide substituted xanthine derivatives with gluconeogenesis modulating activity | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| CN-101356159-A | Substituted isoquinoline-1, 3(2H,4H) -diones, 1-thio-1, 4-dihydro-2H-isoquinoline-3-ones and 1, 4-dihydro-3 (2H) -isoquinolones and their use as kinase inhibitors | WYETH CORP (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-100361992-C | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| CN-1751044-A | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | CN | disclosed |
| CN-1659168-A | Amide-substituted xanthine derivatives having gluconeogenesis modulating activity | HOFFMANN LA ROCHE (CH) | 2005-08-24 | — | — | CN | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | SLC7A5 3402/4885ALOX15 219/4885CA12 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.